anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In 2004, the American Academy of Pediatrics disseminated clinical practice guidelines for the management of neonatal hyperbilirubinemia. Using the infant's age in hours, serum bilirubin levels are applied to hour-specific nomograms to assess risk of developing significant hyperbilirubinemia as well as the necessity for treatment. Prior guidelines did not include nomograms for either. A systems approach to managing neonatal hyperbilirubinemia, including use of the nomograms, has been shown to improve outcomes and patient safety.

Despite the existence of these guidelines, decision support does not exist within MGH clinical information systems for managing neonatal hyperbilirubinemia. We propose to create BiliCurves, an application that integrates perinatal information from the obstetrical health record with that of the newborn's, providing seamless reporting of neonatal bilirubin results in the context of the practice guidelines and relevant obstetrical data. BiliCurves will graphically superimpose bilirubin results onto hour-specific guideline nomograms that providers can view when viewing bilirubin results. We propose to randomize BiliCurves access to pediatric providers, and study its effects on management of hyperbilirubinemia both during birth hospitalization as well as in the outpatient setting after discharge. We hypothesize infants treated by physicians with BiliCurves access will receive birth hospitalization phototherapy at a higher rate and readmission for hyperbilirubinemia at a lower rate than that of the control group. We also hypothesize that physicians with BiliCurves access will report greater ease and confidence in nomogram use and providing evidence-based care as BiliCurves obviates the provider having to have access to paper based versions of the nomogram (usual care) as well decreases potential errors in plotting test results on the nomograms.
The control group is given conventional nursing care: ①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified "human" elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support.This group is planned to enroll 100 patients.
Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
This study will be a randomized controlled trial in which 28 sample sizes will be taken. The participants will be allocated into two groups of 14 participants in each group. One group will perform split body exercises in which 4 days of training will include and every day a single muscle group will be targeted for example on day one the arm muscles bicep and triceps are included and on day two leg press will include and so on. In the second group whole body resistance exercises will perform in two days for example on day one bench press leg press and other resistance training exercises will be performed. Training will give to both groups for 6 weeks. After 6 weeks we compare both groups by FMS and the Leg press bench press test will perform. Data will be analyzed by using SPSS version 25.
The invention discloses a formula, preparation method and application of a compound used for treating acute and chronic pharyngitis. The formula of the traditional Chinese medicine is characterized in that the ingredients consists of 10 to 2,000 grams of Baikal skullcap root, 8 to 1,000 grams of cannabifolius and 5 to 800 grams of cornu bubali, and the combined functions of the medicinal ingredients are dialectically utilized to treat throat swelling and soreness, pharyngeal dryness, pharyngeal itching, xerostomia, thirst, irritable cough, viscous expectoration, hoarse throat and aphonia caused by acute and chronic pharyngitis and also tonsillitis and upper respiratory tract infection. The formula contains a special local ingredient, cannabifolius, in Mount. Changbai, used together with Baikal skullcap root and cornu bubali and has the characteristics of simple prescription and low cost. Compared with the prior formula, the formula has definite characteristics and advantages. Preliminary pharmacodynamics proves that the compound used for treating acute and chronic pharyngitis has a significant treatment effect on the prevention and treatment of throat diseases.
OBJECTIVES: Recent clinical practice guidelines recommend that decisions regarding lumbar puncture (LP) for febrile infants older than 28 days should no longer be based on urinalysis results, but rather independently determined by inflammatory markers and sometimes guided by shared decision-making (SDM). This study sought to assess management decisions for febrile infants aged 29 to 60 days with an abnormal urinalysis.
METHODS: A scenario-based survey was sent to emergency department physicians at all 15 Canadian tertiary pediatric centers. Participants were asked questions regarding management decisions when presented with a well-appearing febrile infant in the second month of life with either an abnormal or normal urinalysis.
RESULTS: Response rate was 50.2% (n = 116/231). Overall, few respondents would perform an LP based on either an abnormal or normal urinalysis alone (10.3% and 6.0%, respectively). However, regression analysis demonstrated that decisions regarding LP were influenced by urinalysis results ( P < 0.001), with respondents more likely to defer to inflammatory marker results for infants with a normal urinalysis result (57.8%) compared with those with an abnormal urinalysis (28.4%). Hospitalization (62.1%) and empiric antibiotic treatment by intravenous route (87.9%) were both frequent for low-risk infants with an abnormal urinalysis. Nearly half of respondents reported rarely (<25% of encounters) engaging families in SDM regarding LP decisions.
CONCLUSIONS: Knowledge translation initiatives reflecting current evidence should target use of inflammatory markers rather than urinalysis results to guide decisions regarding LP. Efforts emphasizing outpatient management with oral antibiotics and SDM for low-risk infants with an abnormal urinalysis could also further align management with current evidence and guidelines.
TADS is a randomized controlled clinical trial that will compare the effectiveness of established treatments---cognitive-behavioral psychotherapy, medication management, and their combination---for adolescents suffering from major depressive disorder (MDD).

The experimental design consists of three treatment stages and a follow-up phase. Stage I (12 weeks) is a four-group randomized comparison of four treatments: antidepressant medication alone (Fluoxetine); psychotherapy alone (CBT); a combination of the medication and psychotherapy (Comb); and a placebo control medication condition (Pbo). Stage II (six weeks) is a treatment consolidation phase in which we ask whether longer treatment in responders and higher intensity treatment in partial responders to their Stage I treatment would be helpful. Non-responders at the end of Stage I will be referred to open community treatment, or for ethical and practical reasons in the case of non-responders to Placebo, to open treatment of their choice with one of the three active study treatments administered by the study team. Responders at the end of Stage I advance to 6 weeks of maintenance treatment in their assigned arm. Partial responders to CBT receive an additional 6 weeks of CBT in their assigned arm; partial responders to Fluoxetine may receive a higher dose for six weeks. Partial responders to the Comb treatment will receive an additional 6 weeks of CBT and may receive a higher dose of medication for six weeks. Stage III (18 weeks) is a treatment maintenance phase for those teenagers who have continued to respond well. Treatment will be continued and progress will be monitored. Stage IV (one year) is an assessment-only follow-up phase to help us understand the long-term benefits of the treatments.

The recruitment strategy is designed to enter into treatment a volunteer clinical sample of 432 teenagers, both males and females, ages 12 to 17, at ten sites. A multiple gating procedure will be used in which patients will be screened, assessed for study eligibility, and if eligible, consented before randomization to one of the four treatment groups. Patients will be selected without regard to race, gender, or ethnicity and it is expected that the sample will match patients seen in general clinical practice. Patients will be recruited from multiple sources including: mental health identified children, i.e., children already coming to a clinic; primary care identified children (pediatric and family physicians); teacher or school identified children (i.e., school refers through the parents or primary caretaker); and families who self-refer.
Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
The invention relates to a Chinese patent medicine, in particular to a traditional Chinese medicine watered pill preparation for treating advanced ovarian cancer. Ovarian cancer is a disease difficult to treat, is not easy to detect early, and is basically advanced when being detected. A patient with advanced ovarian cancer is poor in prognosis, and relapse appears easily after an operation. According to the traditional Chinese medicine watered pill preparation disclosed by the invention, expectant treatment and modification according to symptoms are applied skillfully and complement each other. The traditional Chinese medicine watered pill preparation comprises the following traditional Chinese medicine ingredients: turtle carapace, tortoise shell, dandelion, patrinia, nightshade, oldenlandia diffusa, barbated skullcup herb, areca seed, myrrh, pseudobulbus cremastrae seu pleiones, pangolin scales, dormant insect, fritillaria, baical skullcap root, pinellia ternate, bile arisaema, common selfheal fruit-spike, areca peel, common burreed rhizome, zedoray rhizome, blister beetle and Chinese angelica. The ingredients are combined and together have the effects of promoting qi to invigorate the circulation of blood, softening hard mass to remove disease, promoting diuresis, removing sputum, resolving toxin and dissipating stasis. The curative effect of the traditional Chinese medicine watered pill preparation is better than that of western medicine chemotherapy, modification according to symptoms can be realized, the symptoms of a patient are relieved, the living quality of the patient is improved, and the living time of a terminal cancer patient is prolonged.
PURPOSE: A Sorghum bicolor Moench extract having an antibacterial activity is provided to prevent side effects by human body toxicity accumulation and to use as an alternative agent of conventional synthetic antibacterial agent. CONSTITUTION: A Sorghum bicolor Moench extract is isolated using low alcohol, methanol. The Sorghum bicolor Moench extract is fractioned using hexane, ethyl acetate, n-butanol or water. A cosmetic composition for anti-bacteria contains the Sorghum bicolor Moench extract as an active ingredient. The composition has antibacterial activities to Staphylococcus aureus, Escherichia coli, Salmonella typhimurium, or Klebsiella pneumoniae. The cosmetic composition is used in the form of skin softener, nutrition skin, nutrition cream, essence, pack or shower powder.
INTRODUCTION: Ultrasound (US) has an important place in imaging ulceroglandular type patients with tularemia. This study is a case series addressing the imaging findings of US and US shear-wave elastography in ulceroglandular type tularemia.
DESCRIPTION: Three patients, two women, and one man, were included in our case series. The patients were admitted to our hospital with neck swelling, pain, and a palpable mass. After the diagnosis of tularemia was made as a result of the examinations performed on the patients, they were evaluated again with US and US shear-wave elastography.
DISCUSSION: Since there are many diagnoses including ulceroglandular tularemia in the differential diagnosis of swelling, pain, and palpable mass in the neck, the patient must undergo a thorough evaluation process. US shear-wave elastography can provide significant benefits in identification and treatment follow-up in order to understand the ulceroglandular mass formation observed in the neck in tularemia and the stiffness and morphology of the tissues in the lymph nodes where involvement is observed and to distinguish them from the surrounding tissue.
The present invention provides clonal pluripotent hepatic stem cells using flow cytometry and in vitro single-cell-based assays. These cells possess multilineage differentiation potential and self-renewing capability. These cells could be clonally propagated in culture, where they continuously produced hepatocytes and cholangiocytes as descendants while maintaining primitive stem cells. When cells that expanded in vitro were transplanted into recipient animals, they morphologically and functionally differentiated into hepatocytes and cholangiocytes, with reconstitution of hepatocyte and bile duct structures. Furthermore, these cells differentiated into pancreatic ductal and acinar cells or intestinal epithelial cells when transplanted into pancreas or duodenal wall. These data indicate that self-renewing multipotent stem cells persist in the developing mouse liver and that such cells can be induced to become cells of other organs of endodermal origin under appropriate microenvironment. Manipulation of hepatic stem cells may provide new insight into therapies for diseases of the digestive system.
OBJECTIVE: For elective cesarean section patients with gestational diabetes mellitus (GDM), there is a lack of evidence-based research on the use of enhanced recovery after surgery (ERAS). This study aims to compare the ERAS after-surgery protocol and traditional perioperative management.
RESEARCH DESIGN AND METHODS: In this retrospective cohort study, singleton pregnancies with good glucose control GDM, delivered by elective cesarean sections under intravertebral anesthesia at least 37 weeks from January 1 to December 31, 2022, were collected at the Third Affiliated Hospital of Sun Yat-sen University. We divided all enrolled pregnant women and newborns into an ERAS group and a control group (the traditional perioperative management group) based on their adherence to the ERAS protocol. The primary outcome was the preoperative blood glucose level, with an increase of more than 1 mmol/L indicating clinical significance when compared to the control group. The secondary outcome was centered around an adverse composite outcome that affected both mothers and newborns.
RESULTS: We collected a total of 161 cases, with 82 in the ERAS group and 79 in the control group. Although the mean preoperative blood glucose level in the ERAS group was significantly higher than in the control group (5.01 ± 1.06 mmol/L vs. 4.45 ± 0.90 mmol/L, p<0.001), the primary outcome revealed that the mean glycemic difference between the groups was 0.47 mmol/L (95% CI 0.15-0.80 mmol/L), which was below the clinically significant difference of 1 mmol/L. For the secondary outcomes, the ERAS group had an 86% lower risk of a composite adverse outcome compared to the control group. This included a 73% lower risk of perioperative maternal hypoglycemia and a 92% lower rate of neonatal hypoglycemia, all adjusted by age, hypertensive disorder of pregnancy, BMI, gestational weeks, primigravidae, primary pregnancy, GDM, surgery duration, and fasting glucose.
CONCLUSION: Implementing a low-dose carbohydrate ERAS in pregnant women with GDM prior to elective cesarean section, compared to traditional perioperative management, does not lead to clinically significant maternal glucose increases and thus glucose-related maternal or neonatal perioperative complications.
Idiopathic pulmonary fibrosis (IPF) is the archetypal interstitial lung disease. It is a chronic progressive condition that is challenging to manage as the clinical course of the disease is often difficult to predict. The prevalence of IPF is rising globally and in Japan, where it is estimated to affect 27 individuals per 100,000 of the population. Greater patient numbers and the poor prognosis associated with IPF diagnosis mean that there is a growing need for disease management approaches that can slow or even reverse disease progression and improve survival. Considerable progress has been made in recent years, with the approval of two antifibrotic therapies for IPF (pirfenidone and nintedanib), the availability of Japanese treatment guidelines, and the creation of global and Japanese disease registries. Despite this, significant unmet needs remain with respect to the diagnosis, treatment, and management of this complex disease. Each of these challenges will be discussed in this review, including making a timely and differential diagnosis of IPF, uptake and adherence to antifibrotic therapy, patient access to pulmonary rehabilitation, lung transplantation and palliative care, and optimal strategies for monitoring and staging disease progression, with a particular focus on the status in Japan. In addition, the review will reflect upon how ongoing research, clinical trials of novel therapies, and technologic advancements (including artificial intelligence, biomarkers, and genomic classification) may help address these challenges in the future.
Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
The GARDENIA registry will collect real-world clinical data on the utilization of oral anticoagulants in patients with atrial fibrillation (AF) at elevated risk of stroke. Patients with AF who meet 1 or more of the following criteria will be recruited: advanced age, renal dysfunction, the need for concomitant antiplatelet use, or otherwise judged to be at a higher risk of bleeding. Patients with these criteria are frequently not treated with currently approved oral anticoagulants or they are 'undertreated' based on the use of non-recommended doses of anticoagulants. These patients will be described with regards to baseline demographics and characteristics with particular attention focused on physician and patient factors that may play a role in the under use of guideline-recommended anticoagulation therapy for stroke prevention in patients with AF. Patients in the registry will also be followed to determine the rates of discontinuation/switching of their anticoagulation therapy, incidence of major adverse cardiovascular events and clinically relevant outcome events related to the selection of their anticoagulation therapy. The collected real-world data will be used to inform future studies of patients with AF at elevated risk of stroke.
A preparation for oral administration in the form of a tablet or capsule e.g. gelatin capsule, for the treatment of trichomonas vaginalis vaginitis, contains 2-acylamino-5-nitrothiazole of formula: <FORM:0759274/VI/1> R being an acyl group preferably having up to 10 carbon atoms or being a lauroyl radical e.g. acetyl, propionyl, butyryl, iso-butyryl, caproyl, in intimate admixture with an inert solid diluent e.g. binders, lubricants, and preferably alkaline materials.  The preparation is mixed in a moist condition, granulated, compressed into tablet form and may be coated in gelatin before covering with an enteric coating such as acid-insoluble, alkali-soluble ion exchange resins, high melting fats and waxes e.g. carnauba and beeswax, lipid materials e.g. glyceryl esters of fatty acids, esters of polyhydric compounds e.g. long chain fatty acid partial esters and their oxyalkylene derivatives of hexital anhydrides; resins e.g. gum-mastic, shellac, rosin; fat soluble compounds e.g. abietic acid, bile acids and cholestrol; cellulose derivatives e.g. cellulose nitrate, acetate, phthalate, acetatephthalate; and non-toxic, water-soluble salts of polyvinyl phthalates and phenyl salicylates.  Examples of inert diluents are lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch.  Examples of binders are acacia, zein, tragacanth, gelatin, sodium carboxymethyl-cellulose and methyl cellulose.  Examples of lubricants are mineral oils, stearic acid, magnesium and zinc stearate, stearyl alcohol and mono- or poly-glycol esters. Satisfactory alkaline materials are aluminium hydroxide, disodium phosphate, dipotassium phosphate, sodium carbonate and bicarbonate, and alkaline or alkaline earth metal salts of glycine.
The isochorismate synthase (ICS) proteins are essential regulators of salicylic acid (SA) synthesis, which has been reported to regulate resistance to biotic and abiotic stresses in plants. Clubroot caused by Plasmodiophora brassicae is a common disease that threatens the yield and quality of Oilseed rape (Brassica napus L.). Exogenous application of salicylic acid reduced the incidence of clubroot in oilseed rape. However, the potential importance of the ICS genes family in B. napus and its diploid progenitors has been unclear. Here, we identified 16, 9, and 10 ICS genes in the allotetraploid B. napus, diploid ancestor Brassica rapa and Brassica oleracea, respectively. These ICS genes were classified into three subfamilies (I-III), and member of the same subfamilies showed relatively conserved gene structures, motifs, and protein domains. Furthermore, many hormone-response and stress-related promoter cis-acting elements were observed in the BnaICS genes. Exogenous application of SA delayed the growth of clubroot galls, and the expression of BnaICS genes was significantly different compared to the control groups. Protein-protein interaction analysis identified 58 proteins involved in the regulation of ICS in response to P. brassicae in B. napus. These results provide new clues for understanding the resistance mechanism to P. brassicae.
PURPOSE:To provide the titled plaster comprising an aqueous gel composition composed mainly of a reaction product obtained by the reaction of polyvinyl pyrrolidone with a polyacid compound or its alkali metal salt at a specific pH. CONSTITUTION:Polyvinyl pyrrolidone (having an average molecular weight of 5,000-500,000) is made to react with a polyacid compound (e.g. copolymer of vinyl methyl ether and maleic anhydride) or its alkali metal salt at a weight ratio of 1:4-4:1 at 5-7pH. The obtained aqueous gel is mixed with a polyhydric alcohol such as glycerol, propylene glycol, etc. and an inorganic filler such as kaolin, bentonite, etc. to obtain the plaster for poultice. The amount of the alcohol and the filler are 10-60wt% and 5-40wt% of the total weight of the plaster, respectively. The plaster can include a large amount of water, keeps its gelatinous state even at 70-80 deg.C, and can be applied closely to the skin keeping its flexibility and stretchability. It can be released from the skin without leaving residues to the skin.